Lineage, Inc. Common Stock (LINE)vsChiron Real Estate Inc. (XRN)
LINE
Lineage, Inc. Common Stock
$41.88
-1.16%
REAL ESTATE · Cap: $10.62B
XRN
Chiron Real Estate Inc.
$35.12
-0.43%
REAL ESTATE · Cap: $580.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 3437% more annual revenue ($5.36B vs $151.53M). LINE leads profitability with a -2.7% profit margin vs -5.1%. XRN earns a higher WallStSmart Score of 45/100 (D+).
LINE
Hold36
out of 100
Grade: F
XRN
Hold45
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Strong operational efficiency at 23.4%
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : XRN
The strongest argument for XRN centers on Price/Book, Operating Margin. Revenue growth of 10.1% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : XRN
The primary concerns for XRN are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
XRN carries more volatility with a beta of 1.12 — expect wider price swings.
XRN is growing revenue faster at 10.1% — sustainability is the question.
XRN generates stronger free cash flow (11M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
XRN scores higher overall (45/100 vs 36/100) and 10.1% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Chiron Real Estate Inc.
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
Chiron Real Estate Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?